Gpax Pharmaceuticals Private Limited - Due diligence report

A 360° intelligence report on Celogen Generics: trust score, financial health, credit view, compliance, directors, growth and distress signa…

2014-09-30 Navi Mumbai, Maharashtra Active Unlisted Active Compliant
Share
GP Gpax Pharmaceuticals Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Celogen Generics — 360° Intelligence Report

Generated from MCA filings & public records
65/100
Trust Score
Moderate

Celogen Generics is assessed as Moderate with a Trust Score of 65/100. Celogen Generics is an active private limited indian non-government company incorporated in 2014, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.

Report generated on 20 Jul 2026 from the latest processed filings. Gpax Pharmaceuticals Private Limited snapshot & full profile →

Financial Health › Caution
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
65/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
86/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
5/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
40/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
45/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
55/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 40/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.

Charges position: 6 open (17.38 cr) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
Nkgsb Co.Op. Bank Ltd.2 48.0 cr
Others4 48.0 cr
Compliance Score: 86/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 2 court forum(s).
  • 1 active GST registration(s).
Legal cases on record (2)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
ANUJ SOMCHAND BHAGWANJI SHAH 01234567 Director 01/04/2018 6 yrs Approved
AMIT RAJAN 01234567 Director 01/04/2018 6 yrs Approved
VIKASH NARESH SHAH 01234567 Director 01/04/2018 6 yrs Approved
Bharat Kakubhai Katariya 01234567 Director 01/04/2018 6 yrs Approved
Shailesh Kakulal Kataria 01234567 Director 01/04/2018 6 yrs Approved
RABI NARAYAN NAYAK 01234567 Director 01/04/2018 6 yrs Approved
THYKOOTTATHIL RAJAN MATTHEWS 01234567 Director 01/04/2018 6 yrs Approved
VIJAYKUMAR VAZAKTTUVALIYA RAGHAVAN NAIR 01234567 Director 01/04/2018 6 yrs Approved
  • 8 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
4 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 45 · Distress 55
Growth signals & trust indicators
EPFO headcount growing - hiring signal.
Operating for 11+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Negative net worth.
6 open charge(s) registered - assets are encumbered.
2 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence70/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment41/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 6 open charge(s) of 17.38 cr already registered.
  • Compliance record supports lending.
Investor view36/100
Limited indicators at present
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
19 Jan 2024
Director appointed
ANUJ SOMCHAND BHAGWANJI SHAH (Director)
Director appointed
VIKASH NARESH SHAH (Director)
Director appointed
Bharat Kakubhai Katariya (Director)
Director appointed
Shailesh Kakulal Kataria (Director)
31 Mar 2023
Charge created
Others - 2.55 cr
30 Mar 2021
Director ceased
VIKASH NARESH SHAH
01 Sep 2020
Director ceased
AAKASH VITHALBHAI PATEL
27 Jul 2018
Charge created
Others - 97.50 Lakh
18 Jul 2018
Charge created
Others - 2.50 cr
29 Sep 2016
Director ceased
ANUJ SOMCHAND BHAGWANJI SHAH
Director ceased
AMIT RAJAN
Director ceased
VITHALBHAI DEVJIBHAI PATEL
26 Oct 2015
Charge created
Nkgsb Co.Op. Bank Ltd. - 85.00 Lakh
10

Key Observations

Auto-generated from the data above
Revenue declined 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Compliance record is strong - status, filings and flags are clean.
8 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Capital has been raised through 4 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Unilay Coatings Private Limited U24110MH2019PTC328659 Nashik, Maharashtra, India
Lg Chem U25203AP1996PTC025917 Chittoor, Andhra Pradesh, India
Aptra Synthesis Private Limited U24304TG2020PTC140420 Hyderabad, Telangana, India
Kachhawa Cast Forge Private Limited U74999RJ2019PTC064420 Alwar, Rajasthan, India
Aapchem Private Limited U24290GJ2022PTC134707 Vadodara, Gujarat, India
Primee Silicones (Chennai) Private Limited U24100TN2012PTC088069 Ambattur, Tamil Nadu, India
Punarjan Ayurveda Private Limited U74999TG2017PTC118129 Tirumalagiri, Telangana, India
Pcbl (Tn) Limited U40106WB2020PLC240128 Kolkata, West Bengal, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Celogen Generics before audits and certifications: compliance score 86/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Celogen Generics: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Enhanced diligence advised. Credit risk score 40/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Limited indicators at present. Growth score 45/100, margin trends, ownership structure and peer set for Celogen Generics - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 65/100, distress signals and MSME payment-delay disclosures - know whether Celogen Generics pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Celogen Generics - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Celogen Generics an active company?

Celogen Generics has MCA status “Active” with a compliance score of 86/100 (Low Risk).

Is Celogen Generics financially healthy?

Celogen Generics has a Financial Health Score of 5/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Celogen Generics?

Its overall Trust Score is 65/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Celogen Generics?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 8 active director(s) are on record.

Does Celogen Generics have loans or charges against its assets?

6 open charge(s) are registered against its assets.

Is Celogen Generics up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 86/100 (Low Risk).

Is it risky to lend to Celogen Generics?

Its Credit Risk Score is 40/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.